Jacobio Pharmaceutical Group Co., Ltd. (Stock code: 1167) announced that the Phase I/IIa clinical study of glecirasib (its KRAS G12C inhibitor) in combination with the SHP2 inhibitor JAB-3312 (sitneprotafib) has been published in The Lancet Respiratory Medicine. This marks the first comprehensive clinical data release of an all-oral KRAS G12C + SHP2 inhibitor combination in a top-tier medical journal.

The open-label study enrolled 171 patients in China with KRAS G12C–mutated non-small cell lung cancer (NSCLC), including 102 who had not received prior treatment. The combination therapy achieved a 71% objective response rate and 12.2 months median progression-free survival in the first-line population. A Phase III clinical trial comparing this dual oral combination with the existing standard of care has already commenced in China.

Jacobio focuses on novel molecular targets across six major signaling pathways: KRAS, immune checkpoints, tumor metabolism, P53, RB, and MYC. The company operates R&D centers in Beijing, Shanghai, and Boston, applying its Induced Allosteric Drug Discovery Platform (IADDP) and immunostimulatory antibody-drug conjugate (iADC) platform to further its pipeline.